• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高危人群队列中脑血管疾病和淀粉样蛋白的发病年龄及其对认知的影响。

Onset ages of cerebrovascular disease and amyloid and effects on cognition in risk-enriched cohorts.

作者信息

Du Lianlian, Planalp Elizabeth M, Betthauser Tobey J, Jonaitis Erin M, Hermann Bruce P, Rivera-Rivera Leonardo A, Cody Karly A, Chin Nathaniel A, Cadman Robert V, Johnson Kevin M, Field Aaron, Rowley Howard A, Mueller Kimberly D, Asthana Sanjay, Eisenmenger Laura, Christian Bradley T, Johnson Sterling C, Langhough Rebecca E

机构信息

Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI 53792, USA.

Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI 53792, USA.

出版信息

Brain Commun. 2025 Apr 19;7(3):fcaf158. doi: 10.1093/braincomms/fcaf158. eCollection 2025.

DOI:10.1093/braincomms/fcaf158
PMID:40337464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12056727/
Abstract

The temporal relationship between cerebrovascular disease (V), indicated by white matter hyperintensities, and beta-amyloid (A) in Alzheimer's disease remains unclear, prompting speculation about their potential interdependence. Longitudinal data were employed to estimate onset ages and corresponding disease chronicity for A and V (where disease chronicity is calculated as age at measurement minus estimated age of biomarker abnormality onset). In a large, predominantly cognitively unimpaired dataset ( = 877, ages 43-93 years), a V+ threshold was identified, and Sampled Iterative Local Approximation (SILA) was utilized to illustrate the predictable accumulation trajectory of V post-onset. Investigating the temporal association between A and V onset ages and accumulation trajectories in preclinical years, four operationalizations of time were examined across two initially cognitively unimpaired samples ( = 240 primary sample from Wisconsin Registry for Alzheimer's Prevention; = 123 replication sample from Wisconsin Alzheimer's Disease Research Center): (i) chronological age, (ii) estimated V+ chronicity, (iii) years since baseline scan, and (iv) estimated A+ chronicity. Results indicated that while both diseases are age-related, their onsets and trajectories are independent of each other. In addition, results indicated that V and A accumulation trajectories were highly predictable relative to onset of positivity for each biomarker. Cognitive decline across multiple cognitive domains was fastest when both V and A were present based on last available amyloid PET and MRI scan, with greater A chronicity being a more salient predictor of cognitive decline in these samples.

摘要

由白质高信号所指示的脑血管疾病(V)与阿尔茨海默病中的β-淀粉样蛋白(A)之间的时间关系仍不明确,这引发了对它们潜在相互依存关系的猜测。采用纵向数据来估计A和V的发病年龄及相应的疾病病程(其中疾病病程计算为测量时的年龄减去生物标志物异常发病的估计年龄)。在一个大型的、主要认知功能未受损的数据集(n = 877,年龄43 - 93岁)中,确定了一个V+阈值,并利用抽样迭代局部近似法(SILA)来说明发病后V的可预测积累轨迹。在临床前阶段研究A和V发病年龄及积累轨迹之间的时间关联,在两个最初认知功能未受损的样本中(n = 240,来自威斯康星州阿尔茨海默病预防登记处的主要样本;n = 123,来自威斯康星州阿尔茨海默病研究中心的重复样本)检查了四种时间操作化定义:(i)实际年龄,(ii)估计的V+病程,(iii)自基线扫描以来的年数,以及(iv)估计的A+病程。结果表明,虽然两种疾病都与年龄相关,但它们的发病和轨迹相互独立。此外,结果表明,相对于每种生物标志物阳性的发病,V和A的积累轨迹具有高度可预测性。根据最后一次可用的淀粉样蛋白PET和MRI扫描,当V和A都存在时,多个认知领域的认知衰退最快,在这些样本中,A病程较长是认知衰退更显著的预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/5c7c6e6c596b/fcaf158f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/e30e26d358b6/fcaf158_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/4d888049471e/fcaf158f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/82380970fcfd/fcaf158f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/133cd1a6da7f/fcaf158f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/709e161c2859/fcaf158f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/5c7c6e6c596b/fcaf158f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/e30e26d358b6/fcaf158_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/4d888049471e/fcaf158f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/82380970fcfd/fcaf158f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/133cd1a6da7f/fcaf158f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/709e161c2859/fcaf158f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b2/12056727/5c7c6e6c596b/fcaf158f5.jpg

相似文献

1
Onset ages of cerebrovascular disease and amyloid and effects on cognition in risk-enriched cohorts.高危人群队列中脑血管疾病和淀粉样蛋白的发病年龄及其对认知的影响。
Brain Commun. 2025 Apr 19;7(3):fcaf158. doi: 10.1093/braincomms/fcaf158. eCollection 2025.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.淀粉样蛋白 PET 和 tau-PET 评估唐氏综合征患者症状性阿尔茨海默病的时间轴:一项纵向队列研究。
Lancet Neurol. 2024 Dec;23(12):1214-1224. doi: 10.1016/S1474-4422(24)00426-5.
6
Alzheimer's disease genetic risk and changes in brain atrophy and white matter hyperintensities in cognitively unimpaired adults.认知未受损成年人的阿尔茨海默病遗传风险与脑萎缩及白质高信号的变化
Brain Commun. 2024 Aug 14;6(5):fcae276. doi: 10.1093/braincomms/fcae276. eCollection 2024.
7
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.马克 VCID 脑小血管联盟:一、入组、临床、液体方案。
Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21.
8
Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks.通过淀粉样蛋白和tau PET时钟评估阿尔茨海默病血浆生物标志物变化的时间。
medRxiv. 2024 Nov 14:2024.10.25.24316144. doi: 10.1101/2024.10.25.24316144.
9
Relationship between MRI brain-age heterogeneity, cognition, genetics and Alzheimer's disease neuropathology.脑 MRI 年龄异质性与认知、遗传学及阿尔茨海默病神经病理学的关系。
EBioMedicine. 2024 Nov;109:105399. doi: 10.1016/j.ebiom.2024.105399. Epub 2024 Oct 21.
10
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像(¹⁸F - FDG PET)用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.

本文引用的文献

1
Longitudinal normative standards for cognitive tests and composites using harmonized data from two Wisconsin AD-risk-enriched cohorts.利用两个威斯康星州 AD 风险富集队列的协调数据,制定认知测试和综合指标的纵向规范标准。
Alzheimers Dement. 2024 May;20(5):3305-3321. doi: 10.1002/alz.13774. Epub 2024 Mar 27.
2
T1 and FLAIR signal intensities are related to tau pathology in dominantly inherited Alzheimer disease.T1 和 FLAIR 信号强度与显性遗传性阿尔茨海默病中的 tau 病理学相关。
Hum Brain Mapp. 2023 Dec 15;44(18):6375-6387. doi: 10.1002/hbm.26514. Epub 2023 Oct 23.
3
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
常染色体显性遗传和散发性阿尔茨海默病患者脑白质高信号的病因。
JAMA Neurol. 2023 Dec 1;80(12):1353-1363. doi: 10.1001/jamaneurol.2023.3618.
4
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
5
Evidence against a temporal association between cerebrovascular disease and Alzheimer's disease imaging biomarkers.没有证据表明脑血管病与阿尔茨海默病影像学生物标志物之间存在时间关联。
Nat Commun. 2023 May 29;14(1):3097. doi: 10.1038/s41467-023-38878-8.
6
Longitudinal Relationships of White Matter Hyperintensities and Alzheimer Disease Biomarkers Across the Adult Life Span.大脑白质高信号与阿尔茨海默病生物标志物在整个成年期的纵向关系。
Neurology. 2023 Jul 11;101(2):e164-e177. doi: 10.1212/WNL.0000000000207378. Epub 2023 May 18.
7
White matter hyperintensities in Alzheimer's disease: Beyond vascular contribution.阿尔茨海默病中的脑白质高信号:不仅仅与血管因素有关。
Alzheimers Dement. 2023 Aug;19(8):3738-3748. doi: 10.1002/alz.13057. Epub 2023 Apr 7.
8
The association between white matter hyperintensities and amyloid and tau deposition.脑白质高信号与淀粉样蛋白和tau 沉积的关系。
Neuroimage Clin. 2023;38:103383. doi: 10.1016/j.nicl.2023.103383. Epub 2023 Mar 20.
9
Associations between diffusion MRI microstructure and cerebrospinal fluid markers of Alzheimer's disease pathology and neurodegeneration along the Alzheimer's disease continuum.在阿尔茨海默病连续体中,扩散磁共振成像微观结构与阿尔茨海默病病理学和神经退行性变的脑脊液标志物之间的关联。
Alzheimers Dement (Amst). 2022 Dec 4;14(1):e12381. doi: 10.1002/dad2.12381. eCollection 2022.
10
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.